(VIANEWS) - TPG Specialty Lending (TSLX), First Industrial Realty Trust (FR), Charles River Laboratories (CRL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. TPG Specialty Lending (TSLX)
41.3% sales growth and 8.03% return on equity
Sixth Street Specialty Lending, Inc. (NYSE: TSLX) is a business development company. The fund provides senior secured loans (first-lien, second-lien, and unitranche), unsecured loans, mezzanine debt, and investments in corporate bonds and equity securities and structured products, non-control structured equity, and common equity with a focus on co-investments for organic growth, acquisitions, market or product expansion, restructuring initiatives, recapitalizations, and refinancing. The fund invests in business services, software & technology, healthcare, energy, consumer & retail, manufacturing, industrials, royalty related businesses, education, and specialty finance. It seeks to finance and lending to middle market companies principally located in the United States. The fund invests in companies with enterprise value between $50 million and $1 billion or more and EBITDA between $10 million and $250 million. The transaction size is between $15 million and $350 million. The fund invests across the spectrum of the capital structure and can arrange syndicated transactions of up to $500 million and hold sizeable positions within its credits.
Earnings Per Share
As for profitability, TPG Specialty Lending has a trailing twelve months EPS of $1.36.
PE Ratio
TPG Specialty Lending has a trailing twelve months price to earnings ratio of 13.17. Meaning, the purchaser of the share is investing $13.17 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.03%.Growth Estimates Quarters
For the current quarter, the company expects a decline of 9.5% in growth and a rise of 10.2% the following.Yearly Top and Bottom Value
TPG Specialty Lending's stock is valued at $17.91 at 15:22 EST, way under its 52-week high of $24.36 and way above its 52-week low of $16.02.
Dividend Yield
According to Morningstar, Inc., December 13, 2022 will be the next distribution. The forward-annual dividend rate for 2020 is estimated at 1.8, and the forward annual dividend yield at 10.22%.
Volume
Today's last reported volume for TPG Specialty Lending is 295059 which is 29% below its average volume of 415595.
2. First Industrial Realty Trust (FR)
14% sales growth and 18.19% return on equity
First Industrial Realty Trust, Inc., NYSE: FR, is an industry leader in fully integrated ownership, operator, development, and management of industrial real property. It has a proven track record of providing outstanding customer service to regional and multinational companies. Our local experts are able to manage, lease and buy industrial facilities, as well as regional distribution centers and light industrial in major US markets. We currently own or have in development 64.0 millions square feet of industrial land.
Earnings Per Share
As for profitability, First Industrial Realty Trust has a trailing twelve months EPS of $1.69.
PE Ratio
First Industrial Realty Trust has a trailing twelve months price to earnings ratio of 28.8. Meaning, the purchaser of the share is investing $28.8 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.19%.Sales Growth
First Industrial Realty Trust's sales growth is 13.8% for the ongoing quarter and 14% for the next.
Volume
The volume reported by First Industrial Realty Trust today is 396037, which is 65.84% lower than its average volume 1159500.
Growth Estimates Quarters
The company's growth estimates for the ongoing quarter is a negative 67.8% and positive 3.7% for the next.Moving Average
First Industrial Realty Trust's worth is above its 50-day moving average of $48.12 and below its 200-day moving average of $51.73.3. Charles River Laboratories (CRL)
13.7% sales growth and 17.87% return on equity
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Earnings Per Share
As for profitability, Charles River Laboratories has a trailing twelve months EPS of $7.2.
PE Ratio
Charles River Laboratories has a trailing twelve months price to earnings ratio of 30.56. Meaning, the purchaser of the share is investing $30.56 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.87%.Moving Average
Charles River Laboratories is worth more than its moving average for 50 days of $219.05 or its moving average for 200 days of $231.40.4. Mercer International (MERC)
12.7% sales growth and 44.73% return on equity
Mercer International Inc., together with its subsidiaries, manufactures and sells northern bleached softwood kraft (NBSK) pulp in Europe, the United States, Asia, and internationally. It operates through two segments, Pulp and Wood Products. The company also generates and sells green energy produced from biomass cogeneration power plant to third party utilities. In addition, it manufactures, distributes, and sells lumber and other wood residuals. Further, the company produces NBSK pulp primarily from wood chips, pulp logs, and sawlogs; carbon neutral or green energy using carbon-neutral bio-fuels, such as black liquor and wood waste; and tall oil for use as a chemical additive and green energy source. It sells its pulp to tissue, specialty paper, and printing and writing paper, and other manufacturers; and lumber products to distributors, construction firms, secondary manufacturers, retail yards, and home centers. The company was founded in 1968 and is headquartered in Vancouver, Canada.
Earnings per Share
Mercer International's trailing 12 months EPS is $-0.12.
For the 12 trailing months, the company's return-on-equity, which is a measure of the business' profitability relative to shareholders' equity, was 44.73%.Revenue growth
The year-on-year revenue growth was 13.4%. We now have 2.22B in the 12 trailing months.
Dividend Yield
Morningstar, Inc. estimates that the next dividend payment will be made on September 26, 2022. The forward dividend rate for the year is estimated at 0.3, and the forward dividend yield to be 2.05%.
Annual Top and Bottom Value
Mercer International stock was valued at $11.64 as of 15:22 EST. This is way lower than its 52 week high of $17.50, and higher than its 52-week lowest of $10.83.
5. Perion Network Ltd (PERI)
12.3% sales growth and 19.23% return on equity
Perion Network Ltd. provides digital advertising solutions to brands, agencies, and publishers in North America, Europe, and internationally. It provides Wildfire, a content monetization platform; search monetization solutions, including website monetization, search mediation, and app monetization; and cross-channel digital advertising software as a service platform. The company also offers supply management platform; demand management platform for campaign planning and design; analytics platform, which provides information and performance insights on the results of campaign investment and other campaign metrics; creative platform to create advertisements; and an AI platform that uses machine learning to bring intelligence to the various phases of campaigns. In addition, it provides an actionable performance monitoring platform to support the various phases of campaign management; an online video player and integrated ad server to upload, manage, and stream video content; content monetization system, which integrates ads within the content layouts at the page level. Further, the company offers a publisher management system that provides analytics and performance optimization tools, as well as reports; search-demand management systems; monetization products that integrate and onboards demand vendors; and AI Systems. Additionally, it provides Intelligent HUB (iHUB), a platform for pulling in signals across various advertising channels and optimizing traffic at scale, and yielding engagement metrics and KPIs; and strategic optimization of relevant traits (SORT), a provisional patent technology that eliminates the need for cookies. The company was formerly known as IncrediMail Ltd. and changed its name to Perion Network Ltd. in November 2011. Perion Network Ltd. was incorporated in 1999 and is headquartered in Holon, Israel.
Earnings per Share
Perion Network Ltd's trailing twelve-month EPS is $1.72.
PE Ratio
Perion Network Ltd's trailing 12-month price-earnings ratio is 14.59. The purchaser of the shares is paying $14.59 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the business' profitability relative to shareholders' equity, was 19.23%.6. Zoetis (ZTS)
9.9% sales growth and 47.31% return on equity
Zoetis Inc. develops, produces, markets, and sells diagnostic and animal medicine products, vaccines and other health products both in the United States as well as internationally. The company sells products across all species. This includes livestock such as sheep, cattle, chickens, turkeys, fish and poultry; companion animals including dogs, cats and horses. It also sells vaccines. These are biological preparations designed to prevent disease in the respiratory, digestive, and reproductive tracts. Other pharmaceutical products include antiemetic and reproductive products, pain and sedation products, dermatology products to treat allergic conditions, and medications for livestock. The company also offers portable urine and blood analysis, which includes instruments and reagents for point-of care diagnostics. It can also provide reference kits, laboratory kits, blood glucose monitors, blood glucose monitoring, blood sugar monitors, and rapid immunoassay testing. The company markets its products directly to livestock producers and veterinarians. It also sells its products through third-party distributors. It was established in Parsippany in New Jersey in 1952.
Earnings Per Share
As for profitability, Zoetis has a trailing twelve months EPS of $3.42.
PE Ratio
Zoetis has a trailing twelve months price to earnings ratio of 43.4. Meaning, the purchaser of the share is investing $43.4 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 47.31%.Average Moving
Zoetis's value is lower than its $50.16 moving average and much below its $200.10 moving average.7. Jack Henry & Associates (JKHY)
8.1% sales growth and 25.72% return on equity
Jack Henry & Associates, Inc. offers technology solutions and payment processing service primarily to financial institutions in the United States. It offers transaction and information processing services for banks, from small community institutions to large multi-billion dollar asset institutions, under the Jack Henry Banking name; core data processing for different credit unions under Symitar; and special financial performance, imaging, payments processing, information security, risk management, retail delivery and online solutions to corporate entities and financial institutions. The company also offers a range of integrated apps that can process loan and deposit transactions. It also maintains centralized client/member data. SilverLake is a strong, commercial-oriented banking product. CIF 20/20 for banks, which provides a simple, parameter-driven system that banks can use. Core Director for banks, which offers a more cost-efficient, point-and-click system. Symitar, the company's business brand, offers Episys, which is robustly designed for credit cooperatives. CruiseNet, on the other hand, is a more cost-efficient solution designed specifically for credit unions. The company also offers electronic payments solutions, including the purchase and resell of hardware systems. This includes servers, workstations and scanners. It provides training and support. Jack Henry & Associates, Inc. is a Missouri-based company that was established in 1976.
Earnings Per Share
As for profitability, Jack Henry & Associates has a trailing twelve months EPS of $5.02.
PE Ratio
Jack Henry & Associates has a trailing twelve months price to earnings ratio of 34.97. Meaning, the purchaser of the share is investing $34.97 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.72%.Earnings before Interest, Taxes and Depreciation
Jack Henry & Associates has an EBITDA of 71.62
Growth Estimates Quarters
The company's growth estimates for the ongoing quarter and the next is a negative 12.3% and a negative 0.9%, respectively.Revenue Growth
Year-on-year quarterly revenue growth grew by 8.4%, now sitting on 1.98B for the twelve trailing months.
8. West Pharmaceutical (WST)
5.8% sales growth and 30.76% return on equity
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Earnings Per Share
As for profitability, West Pharmaceutical has a trailing twelve months EPS of $5.57.
PE Ratio
West Pharmaceutical has a trailing twelve months price to earnings ratio of 41.59. Meaning, the purchaser of the share is investing $41.59 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 30.76%.Sales Growth
West Pharmaceutical's sales growth is 5.5% for the ongoing quarter and 5.8% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.6%, now sitting on 2.93B for the twelve trailing months.